Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.
After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful ...
Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...
Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...
Former President Joe Biden jetted off to California hours after President Donald Trump's inauguration. The former president ...
Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...
Masimo Taps Katie Szyman as Permanent CEO Szyman currently serves as the worldwide president of Advanced Patient Monitoring at Becton Dickinson and Co. Defense and Space Company Voyager Technologies ...
Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...